SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading SAGE News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
1.19%177.840.4%$173.61m
VRXValeant Pharmaceuticals International, Inc.
1.08%9.3913.2%$150.67m
PRGOPerrigo Co. Plc
1.44%74.076.1%$144.79m
ALRAlere Inc.
-0.18%49.102.6%$133.79m
JAZZJazz Pharmaceuticals Plc
2.70%162.012.3%$91.66m
UTHRUnited Therapeutics Corporation
0.43%120.5012.9%$89.69m
ENDPEndo International Plc
1.17%11.2810.8%$74.66m
MDCOMedicines Company
-2.35%48.5821.8%$74.51m
MNKMallinckrodt Plc
0.42%46.3917.0%$70.93m
HZNPHorizon Pharma plc
0.91%15.498.2%$42.49m
ICPTIntercept Pharmaceuticals, Inc.
-0.19%113.2322.5%$35.93m
PRXLPAREXEL International Corporation
1.65%63.387.8%$33.46m
ICLRICON Plc
8.25%83.173.9%$32.92m
PCRXPacira Pharmaceuticals, Inc.
1.59%48.0512.2%$30.37m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.70%118.438.2%$28.78m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.